Publications by authors named "Sheila Gaggetta"
Clin Cancer Res
September 2021
Article Synopsis
- This phase I study aimed to assess the safety and effectiveness of gedatolisib, a PI3K/mTORC1/2 dual inhibitor, when used alongside carboplatin and paclitaxel in patients with advanced solid tumors who had received up to two prior treatments.
- Seventeen patients participated, primarily with ovarian (10 clear cell ovarian cancer) and other cancers, with a median treatment history of one previous chemotherapy cycle; the recommended dose for further trials was established to be gedatolisib 110 mg.
- The treatment appeared tolerable, with a 65% overall response rate, notably higher (80%) in patients with clear cell ovarian cancer, although side effects like neutropenia and
